![Ferdinando Nicoletti](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Dr. Ferdinando Nicoletti, MD, is Chairman & Chief Scientific Officer at OncoNOx ApS and a Professor at University of Catania.
Dr. Nicoletti was previously employed as an Advisor by LEO Pharma A, an Advisor by Merck Serono SpA, an Advisor by Amgen BV, an Advisor by Merck Ltd., and an Advisor by Pfizer Inc.
Aktive Positionen von Ferdinando Nicoletti
Unternehmen | Position | Beginn |
---|---|---|
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Gründer | 01.01.2011 |
University of Catania | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Ferdinando Nicoletti
Unternehmen | Position | Ende |
---|---|---|
Merck Ltd. | Corporate Officer/Principal | - |
PFIZER, INC. | Corporate Officer/Principal | - |
Merck Serono SpA
![]() Merck Serono SpA Pharmaceuticals: MajorHealth Technology Merck Serono SpA engages in the manufacture and sale of specialty pharmaceuticals. The company is headquartered in Rome, Italy. | Corporate Officer/Principal | - |
LEO Pharma A/S
![]() LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Amgen BV
![]() Amgen BV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen BV is a Dutch biotech company that specializes in using living cells to create biologic medicines. The company has helped pioneer the biotech industry and are committed to discovering, developing, manufacturing, and delivering innovative human therapeutics to patients suffering from serious illnesses. Amgen's medicines treat serious illnesses and typically address diseases with a limited number of treatment options. The company has a presence in approximately 100 countries and have reached millions of people with their products. Amgen has a robust pipeline focused on the pursuit of transformative medicines with large effects in serious diseases, using human genetic validation whenever possible to strengthen the evidence base for as many of their programs as possible. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Amgen BV
![]() Amgen BV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen BV is a Dutch biotech company that specializes in using living cells to create biologic medicines. The company has helped pioneer the biotech industry and are committed to discovering, developing, manufacturing, and delivering innovative human therapeutics to patients suffering from serious illnesses. Amgen's medicines treat serious illnesses and typically address diseases with a limited number of treatment options. The company has a presence in approximately 100 countries and have reached millions of people with their products. Amgen has a robust pipeline focused on the pursuit of transformative medicines with large effects in serious diseases, using human genetic validation whenever possible to strengthen the evidence base for as many of their programs as possible. | Health Technology |
Merck Serono SpA
![]() Merck Serono SpA Pharmaceuticals: MajorHealth Technology Merck Serono SpA engages in the manufacture and sale of specialty pharmaceuticals. The company is headquartered in Rome, Italy. | Health Technology |
LEO Pharma A/S
![]() LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
Merck Ltd. |